Navigation Links
Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference
Date:5/19/2011

rious medical conditions is one important way to do that. Therefore, CSL Behring seeks to further expand its broad portfolio of products for the hemophilia community, starting with research into a single-chain rFVIII and other promising therapies."

The research leading to the initiation of the studies that CSL Behring is now conducting is the result of collaboration across the CSL Behring research sites in Marburg, Germany, in King of Prussia, PA, USA, and at facilities operated by CSL Limited in Melbourne, Australia.

CSL Behring is also at work on two recombinant fusion proteins (FP) linking coagulation factors with albumin. Both are in testing to demonstrate an extension of factor half life. One, rVIIa-FP (CSL689), is a recombinant factor VIIa albumin fusion protein for the treatment of patients with hemophilia A or B who have developed inhibitory antibodies. The other, rIX-FP (CSL654), is a recombinant fusion protein linking coagulation factor IX with albumin. It is currently recruiting for phase I studies.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema, and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headqua
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Anaphore to Present Company Overview with Focus on Atrimer Technology Platform at 13th Annual C21 BioVentures Conference
2. Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients
3. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
4. Reportlinker Adds Biomarkers: Discovery Techniques and Applications - A Global Market Overview
5. New and Updated Online Tutorials for Ensembl Legacy and Overview of Genome Browsers
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.
7. Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
9. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on The Medical House PLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... the transplant recipient,s immune system identifies the transplanted organ ... thought that T cells, the immune cells that mediate ... chemokines in order to migrate to the transplanted organ. ... Investigation , Fadi Lakkis and colleagues at the University ... of T cells is not required for migration. Instead, ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 The new ... Photonics21 at the association’s recent annual meeting drew ... EC Vice-President Neelie Kroes, who called the action “a ... and a stimulant to European innovation.” , The Board ... of the new Photonics PPP at its 29 April ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine ... achieved 50% enrollment of the total projected enrollment ... the safety and preliminary efficacy of the medical ... for Knee Osteoarthritis (KOA). To date the trial ... The Phase I open label clinical ...
(Date:5/17/2013)... 17, 2013  Insero Health, Inc., a company developing ... and related neurological disorders, is today reporting top-line results ... INS001 in patients with drug-resistant epilepsy.  The data are ... (AED) Xll meeting by Dr. Steven Schachter ... Insero,s Scientific Advisory Board.  In this study, INS001 appeared ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... be deployed broadly to researchers at ... Pfizer, integrated with internal solutions, REDWOOD ... of information solutions for life science researchers, and,Pfizer Pharmaceuticals, ... and pharmaceutical company, announced a strategic,partnership today. This new ...
... Association for Cancer Research ... ... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) announced that it presented ... at the 2008 American Association for Cancer Research (AACR),Annual Meeting. ...
... April 15 BioMed Realty Trust, Inc.,(NYSE: BMR ... its board of,directors concurrently with the company,s annual meeting ... the Ernest W. Hahn Professor of Real Estate Finance ... at the,University of San Diego, has been a member ...
Cached Biology Technology:Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 2Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 3ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 2ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 3ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 4ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 5BioMed Realty Trust Announces Retirement of Mark Riedy From Its Board of Directors 2BioMed Realty Trust Announces Retirement of Mark Riedy From Its Board of Directors 3
(Date:5/20/2013)... forest, popularly known as the lungs of the planet, inhales ... from the air to grow parts that eventually fall to ... region,s plentiful rainfall. , Until recently people believed much ... and ended up deep in the ocean. University of Washington ... of carbon dioxide though left open the question of ...
(Date:5/20/2013)... A National Science Foundation (NSF) planning grant will help ... a joint program of the University of Illinois at ... , "CARD will be devoted to research in drying ... products; forestry and paper products; chemical products; textiles; and ... of food science and human nutrition and the Illinois ...
(Date:5/20/2013)... new study conducted at the University of Bristol and ... Biology sheds light on how the brain and ... from Bristol,s School of Earth Sciences, together with Tom ... the brains of 150 million year old dinosaurs. , ... dinosaur Dysalotosaurus lettowvorbecki : a very young (juvenile) ...
Breaking Biology News(10 mins):Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3NSF approves planning grant for Center for Advanced Research in Drying 2Fossil brain teaser 2
... Angeles, CA Current research suggests that nitric oxide may ... The related report by Mittal et al, "Inhibition of inducible ... phagocytosis of Escherichia coli K1 in neonatal meningitis," ... Journal of Pathology . Bacterial meningitis, or inflammation ...
... WASHINGTON The Proceedings of the National Academy ... PNAS papers to receive the 2009 Cozzarelli Prize, an ... by the National Academy of Sciences. Papers selected for ... articles published by PNAS in 2009 and represent ...
... a multitude of processes and resources in the environment ... include products like clean drinking water and the provision ... Thursday, March 4, the National Science Foundation (NSF) will ... World: Perspectives from Long-Term Ecological Research." The meeting is ...
Cached Biology News:Treating neonatal meningitis -- is nitric oxide a foe or a friend to bacteria? 2PNAS announces six 2009 Cozzarelli Prize recipients 2NSF forum to address 'ecosystem services' in a changing world 2
The Piezo Power MicroDissection (PPMD) system is designed for rapid isolation of single cells or small cell areas...
... a high quality microarray scanner based on patented ... and spatial resolution. The DNAscope LM is ... microarray scanner that is upgradeable to a total ... Includes control module (computer), monitor, ...
... Microarray Slide features an ultra-thin nitrocellulose ... is the first protein microarray slide ... nitrocellulose in a thin film with ... ,The PATH™ Slide can be ...
Request Info...
Biology Products: